Top Markets
#1 GEKKO GEKKO +53.94%
#2 Helium Helium +50.00%
#3 TENDIES TENDIES +45.07%
#4 Pons Pons +39.32%
#5 ADO Protocol ADO Protocol +39.07%
#6 Prom Prom +31.43%
#7 Collector Crypt Collector Crypt +21.07%
#8 o1.exchange o1.exchange +20.78%
#9 Nillion Nillion +20.10%
#10 龙虾 (Lobster) 龙虾 (Lobster) +18.75%
Coin of the day
GEKKO GEKKO
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Rang in Aktien #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Aktienkurs
$1.72
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$981.92M
Veränderung (1 Tag)
-1.68%
Veränderung (1 Jahr)
-41.83%
Land
CN
Handel CARsgen Therapeutics Holdings Limited (2171)

Kategorie

Healthcare
Kursverlauf für CARsgen Therapeutics Holdings Limited (2171)
Höchster Schlusskurs: $1.84 am 2026-08-01

Niedrigster Schlusskurs: $3.97 am 2021-06-01
Kursverlauf der Aktie von CARsgen Therapeutics Holdings Limited von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 6.63%
2025 89.86%
2024 11.34%
2023 -48.93%
2022 -58.99%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH